271 related articles for article (PubMed ID: 32605495)
1. Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura.
Reid JH; Durant KM; Chen SL; Perissinotti AJ; King R; Khoriaty R; Marini BL
J Oncol Pharm Pract; 2020 Oct; 26(7):1695-1702. PubMed ID: 32605495
[TBL] [Abstract][Full Text] [Related]
2. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
Gómez-Seguí I; Fernández-Zarzoso M; de la Rubia J
Expert Rev Hematol; 2020 Nov; 13(11):1153-1164. PubMed ID: 32876503
[No Abstract] [Full Text] [Related]
3. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
4. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
[TBL] [Abstract][Full Text] [Related]
5. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
Elverdi T; Eskazan AE
Drug Des Devel Ther; 2019; 13():1251-1258. PubMed ID: 31118566
[TBL] [Abstract][Full Text] [Related]
6. Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI).
Cid J; Pérez-Valencia AI; Torrente MÁ; Ávarez-Larrán A; Díaz-Ricart M; Esteve J; Lozano M
Transfus Apher Sci; 2021 Feb; 60(1):103011. PubMed ID: 33221124
[TBL] [Abstract][Full Text] [Related]
7. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
Poullin P; Bornet C; Veyradier A; Coppo P
Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
[TBL] [Abstract][Full Text] [Related]
8. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
le Besnerais M; Veyradier A; Benhamou Y; Coppo P
Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
[No Abstract] [Full Text] [Related]
9. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.
Sargentini-Maier ML; De Decker P; Tersteeg C; Canvin J; Callewaert F; De Winter H
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):537-545. PubMed ID: 30977686
[No Abstract] [Full Text] [Related]
10. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic thrombocytopenic purpura in caplacizumab era - An individualized approach.
Sarode R
Transfus Apher Sci; 2023 Apr; 62(2):103682. PubMed ID: 36890095
[TBL] [Abstract][Full Text] [Related]
12. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
[TBL] [Abstract][Full Text] [Related]
13. Caplacizumab: First Global Approval.
Duggan S
Drugs; 2018 Oct; 78(15):1639-1642. PubMed ID: 30298461
[TBL] [Abstract][Full Text] [Related]
14. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
[TBL] [Abstract][Full Text] [Related]
15. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
[TBL] [Abstract][Full Text] [Related]
16. Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.
Bergstrand M; Hansson E; Delaey B; Callewaert F; De Passos Sousa R; Sargentini-Maier ML
J Clin Pharmacol; 2022 Mar; 62(3):409-421. PubMed ID: 34699078
[TBL] [Abstract][Full Text] [Related]
17. Refractory acquired thrombotic thrombocytopenic purpura in a patient with sickle cell trait successfully treated with caplacizumab.
Aggarwal V; Singer Z; Ledingham D; Othman I
Hematology; 2021 Dec; 26(1):590-593. PubMed ID: 34396933
[No Abstract] [Full Text] [Related]
18. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).
Estcourt LJ
Transfus Med; 2019 Jun; 29(3):146-148. PubMed ID: 31318128
[TBL] [Abstract][Full Text] [Related]
19. Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?
Coppo P; Joly BS;
Br J Haematol; 2023 Aug; 202(4):725-727. PubMed ID: 37291806
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment.
Palanques-Pastor T; Megías-Vericat JE; Bosó Ribelles V; Gómez Seguí I; Poveda Andrés JL
Acta Haematol; 2022; 145(1):72-77. PubMed ID: 34352748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
